Salt Lake City

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Fatty liver disease (MASLD/MASH)2 trials

Phase

• Phase 32 trials

Status

• Active, not recruiting1 trial
• Completed1 trial

Lead sponsor

• Akero Therapeutics, Inc2 trials

Running trials

• Active, not recruiting

  A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  NCT06161571· Phase 3· Akero Therapeutics, Inc· Source

Closed trials

• Recruiting

  A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

  NCT06215716· Phase 3· Akero Therapeutics, Inc· Source

  Contact: Akero Study Director